GSK Jumps, Astrazeneca Up | Stock Movers
Community Score: 50% | 5 views | 4w
0 community ratings: null thumbs up, null thumbs down
Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - GSK announced that its Jideytro (zidesamtinib) achieved a 94% objective response rate in TKI-naïve ROS1-positive non-small cell lung cancer patients in the registrational phase I/II ARROS-1 trial, with no placebo comparator. - AstraZeneca’s breast-cancer pill trial failure could cut several billion dollars from the drug’s potential sales, according to analysts. See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information. Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street. Check out more episodes of Stock Movers: https://www.youtube.com/playlist?list=PLe4PRejZgr0NxhJreY_kjMBdW8cvmNauU Visit us: https://www.bloomberg.com/podcasts Follow Bloomberg Podcasts on Twitter: https://twitter.com/podcasts Visit our other YouTube channels: Bloomberg Television: https://www.youtub
Tags: Business, Business News, Daily News, News, bloomberg, bloomberg news, business, finance, investing, investing news, markets, markets news, podcast, radio, stock, stock market, stocks, stocks podcast
More from Bloomberg Podcasts
- Follow the Money All the Way to Carney's Canada — Score: 50%
- Daybreak Weekend: US CPI, Europe Energy, RBA Decision | Bloomberg Daybreak: Europe Edition — Score: 50%
- Bloomberg Money: Credit Card Indicators and Golf's Changing Fanbase | Bloomberg Intelligence — Score: 50%
- We hear you! | Bloomberg Hot Pursuit! — Score: 50%
- Bloomberg Businessweek Weekend - August 7th, 2026 | Bloomberg Businessweek — Score: 50%
- Team Favorite: AI-Era Internet, Spaceport Investment, Bolivia’s Investability | Wall Street Week — Score: 50%